TP53 and cancer: The assessment of p53 IHC staining is predominantly based on protein overexpression, and reported as “positive” or “negative,” or provided as a “percentage.” However, accumulating studies have shown that other IHC patterns, such as a complete absence or cytoplasmic expression, can also indicate a TP53 mutation in several cancer types [7–9].